A Director at Viking Therapeutics (NASDAQ: VKTX) is Buying Shares

By Carrie Williams

Today, a Director at Viking Therapeutics (NASDAQ: VKTX), Stephen Webster, bought shares of VKTX for $41.68K.

This recent transaction increases Stephen Webster’s holding in the company by 100% to a total of $79.92K. In addition to Stephen Webster, 3 other VKTX executives reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

Currently, Viking Therapeutics has an average volume of 57.44M.

Starting in May 2016, VKTX received 36 Buy ratings in a row. Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $10.83, reflecting a -7.8% downside. Four different firms, including Maxim Group and Roth Capital, currently also have a Buy rating on the stock.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. Its clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214.